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Abstract 
Carcinoids are rare, slow-growing tumors originating from a variety of different 
neuroendocrine cell types. They are identified histologically by their affinity for silver salts 
and by positive reactions to neuroendocrine markers such as neuron-specific enolase, 
synaptophysin and chromogranin. They can present with various clinical symptoms and are 
difficult to diagnose. We present the case of a 43-year-old woman who was referred for 
evaluation of anemia. Upper endoscopy showed a duodenal bulb mass around 1 cm in size. 
Histopathological and immunohistochemistry staining were consistent with the diagnosis of 
a carcinoid tumor. Further imaging and endoscopic studies showed no other synchronous 
carcinoid lesions. Endoscopic ultrasound (EUS) revealed a 1 cm lesion confined to the 
mucosa and no local lymphadenopathy. Successful endoscopic mucosal resection of the 
mass was performed. Follow-up surveillance 6 months later with EUS and Octreoscan 
revealed no new lesions suggestive of recurrence. No consensus guidelines exist for the 
endoscopic management of duodenal carcinoid tumors. However, endoscopic resection is 
safe and preferred for tumors measuring 1 cm or less with no evidence of invasion of the 
muscularis layer. 
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Introduction 
The first description of a carcinoid tumor was made by Otto Lubarsch in 1888 [1]. 
However it was Oberndorfer in 1907 who first used the term ‘Karzinoide’ to describe 
a carcinoma-like small bowel tumor that behaved in a benign fashion. The term 
‘carcinoid’ represents a diverse group of neoplasms that arise from various 
neuroendocrine cell types and are characterized by variable biologic aggressiveness. 
Carcinoid tumors most commonly involve the lungs and gastrointestinal tract. 
Carcinoid tumors of the thymus, ovaries, testes, heart and middle ear have also been 
reported. Gastrointestinal carcinoids can secrete bioactive amines and peptides, 
including serotonin, 5-hydroxytryptophan, gastrin, calcitonin, somatostatin and 
glucagon. A common secretory product for all types of carcinoid tumors is the 
glycoprotein chromogranin A (CgA), the most important general tumor marker in these 
patients. 
Little is known about the molecular genetic changes underlying tumorigenesis. 
Sporadic foregut tumors often display allelic losses at chromosome 11q13, and 
somatic MEN1 gene mutations have been reported in one third of sporadic foregut 
tumors. Deletions of chromosomes 18q and 18p have also been reported. Gene 
expression arrays for carcinoid tumors have demonstrated upregulation of the RET 
proto-oncogene, but no such mutations have been detected. 
Primary duodenal carcinoids account for less than 2% of all gastrointestinal 
carcinoids [2]. The annual incidence of duodenal carcinoids is 0.07/100,000 [3]. It is 
higher in males than in females and higher in blacks than in whites. Gastrin cell tumors 
represent the most frequent histopathologic type, accounting for 50–60% of all 
duodenal carcinoids. They can be nonfunctioning or functioning as in Zollinger-Ellison 
syndrome (ZES) and may be associated with the MEN1 syndrome. Somatostatin cell 
tumors represent the second most common type (15–27%). Duodenal carcinoids are 
usually diagnosed on upper endoscopies performed for symptoms such as abdominal 
pain, upper gastrointestinal bleeding and anemia. A few patients with duodenal 
carcinoids (<10%) present with symptoms and/or signs of hormone overproduction. 
ZES occurs in approximately 10% of patients with duodenal carcinoids. Carcinoid 
syndrome may occur in 4%, and in rare cases Cushing syndrome and acromegaly may 
be seen. Diagnosis depends on histopathological examination. Morphologically, gastrin 
tumor cells, which are the most common type, are uniform with rounded nuclei and 
abundant cytoplasm. The growth pattern is usually trabecular or cribriform. Necroses 
are absent and the mitotic rate is low. Most of the tumor cells are positive for 
neuroendocrine markers such as CgA, synaptophysin, Leu7 and neuron-specific 
enolase. Multiple factors must be taken into account when considering treatment 
options. Well-differentiated, nonfunctioning duodenal carcinoids with no evidence of 
invasion of the muscularis layer and 1 cm or less in size can be endoscopically removed. 
These tumors carry a low risk for lymphatic or distant metastasis. Nowadays, 
endoscopic mucosal resection (EMR) is most widely performed. Until now no tumor 
recurrences have been observed which affected overall prognosis of the patient. 
Here we present the case of a woman with a 1 cm duodenal carcinoid that was 
removed by EMR.  
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Case Report 
A 43-year-old woman of Hispanic origin was referred to the gastroenterology clinic for evaluation 
of anemia. She complained of occasional upper abdominal pain, burning in nature, 7/10 in intensity, 
intermittent, nonradiating, worse with food, but no relieving factors. The patient denied any nausea, 
vomiting, fever, chills, changes in bowel habits, dysphagia, odynophagia, hematochezia, melena or 
weight loss. Her past medical history was significant for hypertension and peptic ulcer disease with 
an upper endoscopy 1 year before revealing a gastric ulcer. Her medications included lisinopril, 
ferrous sulfate and multivitamin tablets. Her menstrual periods were regular but occasionally heavy. 
She denied any history of surgeries or use of NSAIDs, tobacco, alcohol or illicit drugs. Her family 
history was not significant either. Vital signs were unremarkable. Pertinent physical examination 
revealed a normal build with mild conjunctival pallor. The respiratory and cardiovascular system 
were unremarkable. The abdomen was soft, nontender, nondistended, with no organomegaly and 
with normoactive bowel sounds. There were no icterus, cyanosis, clubbing, rash, joint swelling or 
deformities noted. Complete blood count showed hemoglobin and hematocrit to be 7.4 g/dl and 
23.9%, with a MCV of 63 fl and a RDW of 18.5%. WBC, platelet count and comprehensive metabolic 
panel were within normal limits. Iron panel showed evidence of iron deficiency anemia with iron 
18 µg/dl, total iron binding capacity 482 µg/dl, ferritin 7 ng/ml and transferrin saturation 4%. Upper 
endoscopy revealed a duodenal bulb mass with heaped-up edges (fig. 1) and a small healing ulcer at 
the prepyloric area with heaped-up mucosa. Histopathologic examination of the duodenal bulb mass 
biopsy was suggestive of a duodenal carcinoid tumor with a solid and trabecular pattern and no 
necrosis. Less than 1/50 HPF mitotic activity was seen. Immunohistochemistry staining was positive 
for both chromogranin and synaptophysin, confirming the diagnosis of a carcinoid tumor. CgA, 
serotonin and 24 h urine 5-HIAA levels were within normal limits. A small bowel series and 
colonoscopy were performed and essentially unremarkable. CT of the abdomen and pelvis showed 
evidence of fatty liver but was otherwise normal. Octreotide scan showed a prominent focal area of 
increased radiotracer uptake in the proximal duodenum correlating with the area of biopsy. 
Examination with a 20 MHz high-resolution endoscopic ultrasound (EUS) probe revealed the 
duodenal bulb mass to be confined to the mucosa. The mass measured approximately 10 mm in its 
largest diameter (fig. 2). Subsequently EMR of the mass was performed. Postresection margins were 
smooth without evidence of residual polypoid tissue. Multiple clips were used to close the mucosal 
defect and prevent delayed bleeding (fig. 3). The resection margins were free of tumor on 
histopathological examination. The patient tolerated the procedure well. Six-monthly surveillance 
EUS revealed no evidence of new lesions or adjacent lymphadenopathy suggestive of any recurrence. 
Repeat Octreoscan failed to show the increased radiotracer uptake in the duodenal bulb seen earlier. 
CgA level was within normal limits. 
Discussion 
To date eight different neuroendocrine cell types have been identified 
ultrastructurally: ECL-, EC-, G-, D-, D1-, A-, P- and X-. Each cell type has characteristic 
neurosecretory granules, some with identified secretory products: enterochromaffin 
cells (EC) secrete serotonin, EC like cells (ECL) secrete histamine, A- cells secrete 
glucagon, D- cells secrete somatostatin, and G- cells secrete gastrin. They are identified 
histologically by their affinity for silver salts and by their positive reactions to 
neuroendocrine markers such as neuron-specific enolase, synaptophysin and 
chromogranin. 
The WHO classification of gastrointestinal endocrine tumors recognizes four 
main tumor categories: (1) well-differentiated endocrine tumor (WDET, carcinoid), 
(2) well-differentiated endocrine carcinoma (WDEC, malignant carcinoid), (3) poorly 
differentiated endocrine (small cell) carcinoma (PDEC), and (4) mixed exocrine-
endocrine tumors. WDET differs from WDEC in the demonstration of distant 
metastases or extensive local growth. The latest figures from the US Surveillance  
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Epidemiology and End Results (SEER) Register show that the number of 
neuroendocrine tumors of the small intestine has increased by 300–500% in the past 
35 years [4, 5]. This has been mainly attributed to the increasing use of endoscopy and 
immunohistochemistry. Other risk factors for small intestinal carcinoids include 
alcohol, female gender, and positive family history [6]. Small intestinal carcinoids also 
occur with an increased frequency in a few inherited syndromes such as MEN1. 
Five major types of neuroendocrine tumors can be seen in the duodenum. 
(1) Gastrinomas (type I) are most common and are usually seen in the proximal 
duodenum. One third are associated with ZES and MEN1. (2) Second in frequency are 
somatostatinomas (type II), which often have a periampullary location. They may be 
associated with von Recklinghausen disease. (3) Gangliocytic paragangliomas (type III) 
are benign tumors found at the ampulla or in the periampullary region. (4) Type IV is 
rare and contains tumors that produce serotonin and calcitonin. (5) PDEC (type V) is 
extremely rare and highly malignant and is usually located at the ampulla of Vater [7]. 
Burke et al. [8] reported 99 cases of duodenal carcinoid tumors, consisting of 59 men 
and 40 women with an average of 59 years. The mean tumor diameter was 18 mm 
(range 2–50 mm). With regard to the lesion site, the duodenal bulb accounted for 43% 
of cases while 52% were found in the second portion of the duodenum. Regarding 
invasion depth, 49% showed submucosal lesions and 51% invasion of the muscularis 
mucosa. Metastasis to the lymph nodes, liver and other sites were observed in 21% [9]. 
Most duodenal carcinoids are asymptomatic and detected during upper 
gastrointestinal endoscopy for unrelated symptoms such as abdominal pain (37%), 
upper gastrointestinal bleeding (21%), anemia (21%) and jaundice (18%). In contrast, 
ampullary carcinoids more frequently cause symptoms with up to 60% presenting with 
jaundice. Duodenal neuroendocrine tumors are usually hormonally silent (60–98%). 
However some may develop ZES (up to 10%) or Cushing syndrome (4%), and rarely 
patients have a duodenal neuroendocrine tumor that is an insulinoma or a 
glucagonoma or even a growth hormone factor-releasing tumor that manifests as 
acromegaly. Very few patients develop carcinoid syndrome characterized by diarrhea, 
flushing, carcinoid heart disease, bronchial constriction and abdominal pain. A 
life-threatening exacerbation of carcinoid syndrome called carcinoid crisis can be 
triggered by anesthesia, drugs or surgery. 
Upper gastrointestinal endoscopy and histological examination form the 
cornerstone for diagnosis. EUS should follow and allows the determination of the size 
and depth of infiltration and also assesses locoregional lymph nodes. It can also 
accurately determine the layer of origin and internal echo pattern. Serum and urine 
neuroendocrine markers (such as CgA and 5-HIAA) may have diagnostic value. CgA 
may also have prognostic significance and can be used during the follow-up of patients. 
Serum gastrin should also be determined, and if elevated in combination with a 
hyperacidic stomach a secretin stimulation test should be done to establish ZES. 
Conventional imaging methods (CT, MRI) can assist with tumor staging and 
localization. Burke et al. [8] identified three pathologic features for the primary tumor 
as independent risk factors for metastasis: invasion of the muscularis propria, size 
>2 cm and presence of mitotic figures. A large variety of carcinoid tumors and their 
metastases can express a high density of specific somatostatin receptors for which 
octreotide, a somatostatin analogue, has high affinity. Octreoscan (using 111In-labeled  
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octreotide) not only helps in detection, but also predicts therapeutic effect of 
somatostatin analogues in these tumors [2]. 68Ga-DOTATOC-PET/CT is a new, very 
sensitive method for visualizing metastatic intestinal carcinoids [5, 10]. Due to frequent 
carcinoid heart disease (30–60% of patients with carcinoid syndrome), every patient 
with carcinoid syndrome should have cardiac imaging. 
A TNM staging of foregut neuroendocrine tumors was recently approved by the 
European Neuroendocrine Tumor Society (table 1). Tumors limited to the lamina 
propria or submucosa and <1 cm are assigned Tx through T1. Tumors >1 cm or 
invading the muscularis propria are categorized T2 or greater [11]. 
Multiple factors such as differentiation, tumor localization, tumor stage and 
patient-related factors must be taken into account when considering treatment options. 
Endoscopic resection has been reported to be a safe, less invasive and effective 
procedure for tumors measuring <1 cm in diameter that are located outside the 
periampullary region, with no EUS signs of invasion of the muscularis layer. The 
appropriate treatment for duodenal carcinoid tumors >1 cm is still controversial. Some 
authors suggest that for tumors 1–2 cm in diameter, operative full-thickness excision is 
preferred. However there has been a case report of a 12 mm duodenal carcinoid tumor 
that was removed via EMR. Nonetheless it may be difficult to remove completely 
endoscopically tumors >1 cm, and they should be evaluated with EUS before an attempt 
at endoscopic resection owing to their potential for invasion beyond the submucosa. 
Endoscopic excision of a primary duodenal carcinoid tumor seems most appropriate 
for tumors ≤1 cm [12]. 
There are no controlled studies on the optimal management of ampullary 
neuroendocrine tumors. Endoscopic papillectomy and surgical tumor resection can be 
curative in early disease whereas patients with ampullary carcinoids >2 cm may benefit 
from Whipple procedure [13]. 
Disclosure Statement 
The authors have no funding or conflicts of interest to disclose. 
 
 
  
Case Rep Gastroenterol 2012;6:135–142 
DOI: 10.1159/000337870 
Published online: 
March 23, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
 
140 
Table 1. TNM staging of foregut neuroendocrine tumors 
        T: primary tumor 
Tx  primary tumor cannot be assessed 
T0  no evidence of primary tumor 
T1  tumor invades the lamina propria or submucosa and size ≤1 cm 
T2  tumor invades the muscularis propria or size >1 cm 
T3  tumor invades the pancreas or retroperitoneum 
T4  tumor invades the peritoneum or other organs 
        N: regional lymph nodes 
Nx  regional lymph nodes cannot be assessed 
N0  no regional lymph node metastasis 
N1  regional lymph node metastasis 
        M: distant metastasis 
Mx  distant metastasis cannot be assessed 
M0  no distant metastasis 
M1  distant metastasis 
         
 
 
 
 
Fig. 1. Upper endoscopy revealing the presence of a duodenal bulb mass with headed-up edges 
(arrow). Histopathological examination of the mass was suggestive of a carcinoid. 
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Fig. 2. EUS view with a high-resolution 20 MHz probe showing the mass (arrow). The mass was 
confined to the mucosa and measured 10 mm in its largest diameter. 
 
 
 
Fig. 3. EMR of the mass was performed. Multiple surgical clips (shown in the figure) were used to 
close the mucosal defect. 
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